<DOC>
	<DOCNO>NCT00311467</DOCNO>
	<brief_summary>Multi-center , prospective randomise phase III study evaluate capecitabine combination standard-immunotherapy versus standard-immunotherapy alone first-line therapy patient metastatic renal cell carcinoma .</brief_summary>
	<brief_title>Combined Treatment With Capecitabine Immunotherapy Versus Immunotherapy Alone Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>Treatment plan Group A Patients randomise group A receive treatment accord follow treatment schedule : Group A : Combined Chemo-Immunotherapy Chemotherapy : Mo-Fr Immunotherapy - Week 1 : Capecitabine / Interferon ; - Week 2 : Capecitabine / Interferon ; - Week 3 : REST PERIOD / Interleukin ; - Week 4 : Capecitabine / Interleukin ; - Week 5 : Capecitabine / REST PERIOD ; - Week 6 : REST PERIOD / Interferon ; - Week 7 : Capecitabine / Interferon ; - Week 8 : Capecitabine / Interleukin ; - Week 9 : REST PERIOD / Interleukin ; - Week 10 : Capecitabine / REST PERIOD ; - Week 11 : Capecitabine / Interferon ; - Week 12 : REST PERIOD / Interferon ; - Week 13 : Capecitabine / Interleukin ; - Week 14 : Capecitabine / Interleukin ; DOSAGES AND ROUTES OF ADMINISTRATION : Capecitabine orally day 1 14 dose 1000 mg/m2 twice daily every 21 day . Interferon-alpha subcutaneously day 1 + 3 + 5 week 1 + 2 +6 + 7,11+12 dose 6 MIU/d . Interleukin-2 subcutaneously day 1 4 week 3 + 4 +8 + 9,13+14 dose 4.5 MIU/day . Group B Patients randomize group B receive treatment accord treatment schedule dosage without capecitabine . Efficacy evaluation perform every 14 week treatment group</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Histologically confirm renal cell carcinoma ( primary tumour biopsy/surgery metastasis ) Radiologically confirm metastatic disease Surgically remove primary tumour feasible ( nephrectomy nephronsparing surgery indicate ) KarnofskyPerformance Status &gt; 70 % Age 1975 year Life expectancy least 3 month Adequate bone marrow function ( i.e . white blood cell count 3000/μL , platelet count 75 000 /μL , hemoglobin 9 mg/dl ) Adequate organ function ( i.e . serum creatinine , bilirubin AST 1.25 x upper limit institution ' normal range ) Negative pregnancy test female patient Written inform consent Age &lt; 19 &gt; 75 year KarnofskyPerformance Status &lt; 70 % Untreated uncontrolled brain metastasis Second neoplasia Primary tumour surgically removable Solitary , surgically removable metastasis Major concomitant diseases cardiovascular , respiratory renal system , well active systemic infection Severe renal disease liver insufficiency myeloid dysfunction ( include patient history disease likely interfere metabolism excretion test medication ) Other less common disease peptic ulcer disease , inflammatory bowel disease , autoimmune disease ( severe know psoriasis , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , rheumatoid arthritis etc . ) Drug addiction ( include excessive alcohol consumption ) within 1 year prior study start . History condition consistent decompensated liver disease evidence bleed form esophageal varix . History chronic hepatitis immunsupressiva Known HIV Infection Evidence allergy hypersensitivity recombinant Interferon alfa2a component preparation . History severe psychiatric disease , especially depression . Severe psychiatric disease define treatment antidepressant medication major tranquilizer therapeutic dos major depression psychosis , respectively , least 3 month previous time history follow : suicidal attempt , hospitalization psychiatric disease , period disability due psychiatric disease . Seizure disorder /or compromised central nervous system function . History evidence severe retinopathy Patient unwilling unable give inform consent Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>renal cell cancer</keyword>
</DOC>